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Abstract
Pancreatic cancer shows extremely low responses to chemo- and radiation therapies due to its inherent genetic
instability, immunosuppressive microenvironment, and the complex peritumoral stroma. They make the pancreatic
cancer most lethal malignancy with 5 year survival of less than 6%, so the need of new therapeutic approaches is
urgently demanded. Immunotherapies have shown promises in other multiple cancers by augmenting anti-tumor
immunity, so it stood out for the alternative care of pancreatic cancer. However, up to now, immunotherapeutic
agents lack efficacy in pancreatic cancer. In this review, we give an overview of immune-related therapeutic
strategies, clinical trials in pancreatic cancer and current obstacles that we face. We discuss the ways to overcome
those current obstacles here, and by getting over them, we hope to get over the poor prognosis of pancreatic
cancer.
Keywords: Immunosuppressive microenvironment; Malignancy;
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Introduction
Pancreatic cancer is the most lethal malignancy with a 5 year
survival of less than 6% [1]. In contrast to the increment in other
cancer survival, the advance in pancreatic cancer is very slow and
despite surgery, locoregional therapy, chemotherapy and radiotherapy,
the overall median survival is still less than 1 year from diagnosis.
Surgical resection is the only curative treatment, but even after surgery,
5 year survival does not reach to 20% [2]. The reason for low objective
response rate to conventional standard therapy is because of the
inherent genetic instability of pancreatic cancer cells,
immunosuppressive microenvironment at the tumor site, and the
complex peritumoral stroma [3,4]. As probe or inhibitor of histone
methyltransferase G9a is able to induce cell senescence or death in
pancreatic carcinoma, more attention has been drawn to disruption
the function of G9a in the treatment of pancreatic adenocarcinoma
[5,6]. However, as apart from being as a histone modifier, G9a is also
essential for the maintenance of global and loci specific DNA
methylation, inhibition of G9a may cause even more severe genetic
instability of pancreatic cancer [7]. Therefore, new strategies, such as
immunotherapeutic methods, need to be studied in order to eradicate
pancreatic carcinoma. Immunotherapy started since the end of the
19th century first by European physician, William Coley, with the idea
of recruiting and activating the host’s T cells to recognize and attack
tumor-specific antigens, by themselves [8,9]. In pancreatic cancer,
from animal models, it is known that pre-invasive pancreatic lesions
contain high density of immune suppressor cells, but nearly absent
immune effector cells, suggesting that antitumor immunity including
cytotoxic and adaptive immunity may be already defective [10].
Therefore, reactivating the antitumor immunity in pancreatic cancer
has been highlighted as a new therapeutic option for the last several
decades. Immunotherapies in pancreatic cancer diverse into 4 main
categories; checkpoint inhibitors/immune modulators, therapeutic
vaccines, adoptive T cell transfer, and monoclonal antibodies.
Checkpoint Inhibitors/Immune Modulators
When the cancer cells or cancer cells expressing proteins are
recognized as antigens, tumor specific T cells are activated. Those cells
are controlled by inhibitory and stimulatory signals, called immune
checkpoints. The blockade of inhibitory immune checkpoints would
induce T cell proliferation and prolong the life of activated T cells,
consequently enhances antitumor immune responses [11]. Cytotoxic
T-lymphocyte associated protein-4 (CTLA-4) and programmed cell
death protein-1 (PD1), CD28 inhibitors are major negative
costimulator expressed on activated T cells [12], and have become the
first clinical landscape in cancer immunotherapy. Despite their success
in certain malignancies, in pancreatic cancer, past phase I and II
clinical trials with ipilimumab (CTLA-4 inhibitor), pidilizumab (anti-
PD1 mAb), CP-870893 (monoclonal antibody of CD40 receptor), and
BMS-936559 (PDL1 antibody) did not prove any effectiveness [13-15].
Due to enhancement of general immunity and temporal
immunosuppression, nearly 10% of patients were undergone G3-4
adverse effects, called ‘immune-related adverse events (irAEs),
including dermatologic, gastrointestinal, hepatic, endocrine, and other
less common inflammatory events [16,17]. To overcome those irAEs,
dose adjustment and temporal use of systemic corticosteroids are
recommended, depends on the severity of events.
Therapeutic Vaccines
Autologous pancreatic cancer cells express several specific antigens,
including Wilms’ tumor gene 1 (WT1) (75% of patients), mucin 1
(MUC1) (over 85%), human telomerase reverse transcriptase (hTERT)
(88%), mutated K-RAS (73%), and carcinoembryonic antigen (CEA)
(over 90%) [18-24]. With the idea of administering these tumor
antigens to stimulate the patients’ own immune system to recognize
them, tumor vaccinations have been tested. There are two major
categories of therapeutic vaccines; whole-cell vaccines and antigen-
specific vaccines. Whole-cell vaccines are made by transfecting human
tumor cell lines with or without granulocyte-macrophage colony-
stimulating factors (GM-CSF); GVAX (GM-CSF) and Algenpantucel-L
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(a-1,3 galactosyl transferase) [25-28]. Despite their promises in post-
surgical patients, for metastatic pancreatic cancer patients, they did not
show any benefits. Antigen-specific vaccines, peptide vaccines, try to
target antigens and other factors expressed by tumor cells; GV1001
(hTERT), Tacemotide (MUC-1), Kras (K-RAS), WT1 (WT1), and
KIF-20A (HLA-A24) [29-34]. This approach has not delivered any
improvement in overall survival or disease free survival. Nonspecific
vaccines like IMM-101 (contains a wide variety of pathogen-associated
molecular patterns (PAMPs)), dendritic cells (DC) also tried, but no
single agent of vaccines proved its efficacy [35,36].
Adoptive T Cell Therapy
T cells are removed from a patient and genetically engineered to
recognize tumor specific proteins, and then re-introduced to the
patient aiming to enhance antitumor responses. Chimeric antigen
receptors (CARs) are transmembrane proteins comprising an
antibody-derived single-chain variable fragment specific for a tumor
antigen fused to a hinge region, a spacer, a membrane spanning
element and signaling domain [37]. CAR therapy has been an
innovative strategy to redirect T cells against tumors and shows
promises in leukemia targeting CD 19 antigen. Up to now, due to less
identified potential antigens and its expensive and time-consuming
process, the progress in pancreatic cancer is very slow [38]. However, if
those problems would be overcome, engineered T cells in CAR therapy
would seem to prove its clear ability to kill tumor cells significantly.
Monoclonal Antibodies
Monoclonal antibodies (mAbs) bind to targeted antigens, same
editopes, expressed on tumor cells and play an inhibitory role by
preventing formation of antigen-ligand complex [39]. MUC-1,
overexpressed in 90% of pancreatic cancer, has been the first target of
mAb in pancreatic cancer; PAM4, clivatuzumab. Starting from MUC-1
mAb, endothelial growth factor receptor (EGFR), EGFR2 (HER2),
vascular endothelial growth factor (VEGFR), CD40, MUC5a, etc. have
been targeted of mAbs, and started clinical trials; no significant
improvement in phase III clinical trials was shown, yet [40-46] (Table
1).
Therapeutic category Investigator Phase Target Agent Patients/N Outcomes
Checkpoint inhibitors Royal et al. [13] II CTLA-4 Ipilimumab Advanced/27 PR: 3.7%
Anjali et al. [14] Ib CTLA-4 Ipilimumab Advanced/ 13 PR: 15%
SD: 38%
Brahmer et al. [15] I PDL-1 Nivolumab Advanced/14 No objective
responses
Therapeutic Vaccines
Whole cell vaccines Jaffee et al. [47] I GM-CSF
vaccine
GVAX with chemotherapy Resected/ 14 DFS greater than
10 years
Laheru et al. [48] II GM-CSF
vaccine
GVAX with cyclophosphamide (Cy) Advanced/ 50 OS benefit with Cy:
2.4 months
Lutz et al. [28] II GM-CSF
vaccine
GVAX with chemoradiotherapy (5-
FU)
Resected/ 60 DFS: 17.3 months
OS: 24.8 months
Hardacre et al. [25] II Algenpantucel-
L
Algenpantucel-L with chemotherapy Resected/ 70 DFS: 62%
OS: 86%
Lutz et al. [49] Pilot GM-CSF
vaccine
GVAX with cyclophosphamide (Cy) Resected/ 54 Vaccine-induced
intratumoral tertiary
lymphoid
aggregation was
observed.
Upregulation of
PD-1 and PD-L1 in
the tumor was
observed after
vaccination.
Antigen-specific
vaccines
Abou-Alfa et al. [29] I K-ras Kras Resected/ 24 DFS: 8.6 months
OS: 20.3 months
Bernhardt et al. [30] I/II hTERT GV1001 Advanced/ 48 OS: 8.6 months
Middleton et al. [31] III hTERT GV1001 with sequential
chemotherapy
Advanced/ 1052 PFS: 4.5%, OS:
6.9%
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GV1001 with concurrent
chemotherapy
PFS: 6.6%, OS:
8.4%
Chemotherapy only PFS: 6.4%, OS
7.9%
Ramanathan et al. [50] I MUC-1 MUC-1 Advanced/ 16 OS: 12.0 months
Mayanagi et al. [32] I WT1 DC Advanced/ 32 PFS: 4.2 months
OS: 8.1 months
Asahara et al. [34] I/II HLA-A24 KIF20A Advanced/ 31 PFS: 2.0 months
OS: 4.7 months
Adoptive T cell
therapy
Beatty et al. [38] I Mesothelin CARTmeso Advanced/ 2 Acceptable safety
in both IV and intra-
tumoral injection
Monoclonal
antibodies
Gulec et al. [40] I MUC-1 PAM4 Advanced/ 20 PR: 15%, SD: 20%
Ocean et al. [41] I MUC-1 PAM4 with gemcitabine Advanced/ 38 PR: 15%, SD: 27%
Philip et al. [42] III EGFR Cetuximab with gemcitabine Advanced/ 745 PR: 8%, SD: 37%
Gemcitabine PR: 7%, SD: 30%
Assenat et al. [43] I/II EGFR/HER2 Cetuximab/Trastuzumab Advanced,
Previously treated/
38
PFS: 1.8 months
OS: 4.6 months
Kindler et al. [44] III VEGFR Bevacizumab with gemcitabine Advanced/ 535 CR/PR: 13%, SD:
42%, PFS: 3.8
months, OS: 5.8
months
Gemcitabine CR/PR: 10%, SD:
34%, PFS: 2.9
months, OS: 5.9
months
Beatty et al. [45] I CD40 CP 807,893 with gemcitabine Advanced/ 21 PR: 19%, SD: 52%
PFS: 5.6 months,
OS: 7.4 months
PR; partial response, SD; stable disease, CR; complete response, PFS; progression free survival, DFS; disease free survival, OS; overall survival
Table 1: Summary of main clinical trials of immunotherapy in pancreatic cancers.
Challenges in Immunotherapy
Up to now, any single agent of immunotherapies in pancreatic
cancer did not prove its efficacy significantly. There are some reasons
for that, but mainly it seems to be thought that pancreatic cancer is
such a heterogeneous disease, requiring polyvalent approaches [51]. It
might be not sufficient to remove the inhibitory immune regulators or
to active innate and cytotoxic immunity, alone. In order to bypass the
immunosuppressive environments and boost immune responses in
pancreatic cancer, an orchestrated approach would be required. Many
preclinical studies support evidences for combination of vaccines with
immune checkpoint inhibitors, and clinical trials begin to show
promises in the treatment of pancreatic cancer; especially clinical trials
for the combination of PD-1 inhibitor and GVAX do [52,53]. To make
further steps possible, we still face two simple questions; 1) whom to
treat, and 2) how to deliver drugs through microenvironment.
Whom to treat
Recent data support that overall response rate to immunotherapy is
around 20% [54-60]. That emphasizes the importance to find the right
person for immunotherapy who would show good response. There
could be two possible approaches; select patients with biomarkers or
with cancer status. Eventually, immunotherapy should extend the
indications to all stages of pancreatic cancer, but it would be more
promising to start with patients of possible minimal residual disease
after resection to prevent recurrence with minimal toxicities. Past
studies were focused on finding serum biomarkers, but yet, no
biomarkers show any benefit. For the GV1001, telomerase peptide
vaccine, high eotaxin levels at baseline were once reported to correlate
with a longer overall survival, but following studies did not find any
correlation between eotaxin levels and overall survival. This distress in
finding serum biomarkers may be due to complex peritumoral stroma
of pancreatic cancer which separates tumor burden from systemic
circulation. If we can stabilize tumor cells obtained by endoscopic or
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percutaneous biopsy from patients, and analyze the specific antigens
for each patient, we can specify the immunotherapy that compatible to
each patient; ‘half-individualized immunotherapy’.
How to deliver
Like other failures of chemotherapy, immunotherapy also has the
same issue; how to deliver immune regulating drugs or activated T
lymphocytes to the cancer. There would be three available approaches
to improve; 1) combination with chemotherapy, 2) combination with
radiotherapy, and 3) in situ immunization. It had been assumed that
chemotherapy could not be used in combination with immunotherapy
because of its immunosuppressive activities for a long time. However,
in the aspects of reducing immune suppressive cells, increasing antigen
presenting cells by cytotoxic activities, and alternative mechanisms of
immunogenicity, chemotherapy is now recognized as providing
additional benefit to immunotherapy. Many preclinical studies support
that theme [61-68], and clinical trials begin to show positive results
[69-77]. Radiotherapy also was known to have potential to be a good
combination therapy with immunotherapy. As we can imagine easily
from its ‘abscopal effect’, radiation can convert the irradiated tumor
into an ‘immunogenic hub’ [78]. Once, tumor have damaged with
radiation exposure, cancer cells dye of apoptosis and necrosis, and
those dead cancer cells promote uptake by dendritic cells, presentation
of tumor-derived antigens to T cells, activation of cytotoxic T cells,
exposure of specific proteins on tumor cell surface, and release of ATP
and high mobility group protein B1 (HMGB1) [79]. Thus, radiation
seems to play an important role in modifying systemic immune system
into more suitable conditions for immunotherapy. Concepts of ‘in situ
immunization’ were started from the idea of how to invade cancer cells
directly. This use of immunotherapy show significant antitumor effect
in bladder cancer, melanoma, and head and neck cancer [80-82]. For
the pancreatic cancer, it is not that difficult to inject drugs into cancer
cells with techniques of endoscopic ultrasonography. In situ
immunization can provide promises to immunotherapy in pancreatic
cancer.
Conclusion
In spite of advances in anticancer treatment, pancreatic cancer
remains a lethal malignancy. Surgery, locoregional therapies,
chemotherapy and radiotherapy could not prove the survival more
than 1 year. Regarding to its immune surveillance characteristics,
immunotherapy has potentials to treat pancreatic cancer more
efficiently. Since 19th century, many advances and clinical trials have
done in the field of immunotherapy, but in pancreatic cancer, it is still
evolving and unexplored landscape. So far, no significant efficacy was
proven in clinical trials of pancreatic cancer and people begin to face
obstacles; whom to treat and how to deliver. If we can get the tumor
tissue from patients efficiently, it might be possible to choose
individualized appropriate target antigens. And combination with
chemotherapy or radiotherapy, or in situ immunization can improve
the efficacy of immunotherapies. There are far ways to go, and many
obstacles to overcome, but as we overcome one obstacle, one patient
can live one month longer.
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